N-(5-Carboxypentyl)-deoxynojirmycin (CAS 79206-70-5)

N-(5-Carboxypentyl)-deoxynojirimycin (CP-DNJ) is a potent iminosugar derivative that has garnered significant attention in glycobiology research due to its unique mechanism of action. CP-DNJ acts as a competitive inhibitor of α-glucosidases, enzymes involved in carbohydrate metabolism and glycoprotein processing. Specifically, it binds to the active site of α-glucosidases, preventing the hydrolysis of terminal glucose residues from glycoproteins and oligosaccharides. This inhibition leads to the accumulation of misfolded glycoproteins in the endoplasmic reticulum and subsequent activation of the unfolded protein response (UPR) pathway. Researchers utilize CP-DNJ as a chemical tool to modulate glycoprotein processing and study the consequences of impaired glycosylation on cellular physiology. Moreover, CP-DNJ has shown promise in studies for managing lysosomal storage disorders and viral infections by disrupting viral glycoprotein maturation and inhibiting viral entry into host cells. Additionally, CP-DNJ derivatives are being investigated for their potential as agents in the management of diabetes, cancer, and neurodegenerative diseases. Through its multifaceted mechanisms of action, CP-DNJ continues to be a valuable tool in deciphering the roles of glycosylation in health and disease.